

Mentice Q1 2023 - Solid Q1 despite tough sales comparatives

Redeye updates its estimates and valuation following Mentice's Q1 2023 report. Notably, positives in the report included strong sales growth and margin expansion. Order intake was mixed, featuring considerable weakness in HCS and SA. We nudge up our base case and valuation range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Mentice Q1 2023 - Solid Q1 despite tough sales comparatives